Does Rallies track congressional trades in BIIB?

Yes. Rallies tracks politician and congressional stock disclosures for BIIB, including reported purchases, sales, dates, owners, and trade amounts when available.

Is BIIB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.

BIIB (Biogen) Stock Analysis - Politician Trades

Biogen (BIIB) is a publicly traded Healthcare sector company. As of May 20, 2026, BIIB trades at $187.75 with a market cap of $28.33B and a P/E ratio of 20.20. BIIB moved -1.35% today. Year to date, BIIB is +7.16%; over the trailing twelve months it is +47.22%. Its 52-week range spans $110.04 to $205.97. Analyst consensus is buy with an average price target of $218.76. Rallies surfaces BIIB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded BIIB stock?

Recent politician trading activity in BIIB includes disclosures from Gilbert Cisneros, Rob Bresnahan, Rob Bresnahan, Ro Khanna, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

BIIB Key Metrics

Key financial metrics for BIIB
Metric	Value
Price	$187.75
Market Cap	$28.33B
P/E Ratio	20.20
EPS	$9.35
Dividend Yield	0.00%
52-Week High	$205.97
52-Week Low	$110.04
Volume	668.76K
Avg Volume	0
Revenue (TTM)	$9.94B
Net Income	$1.37B
Gross Margin	75.49%

Congressional Trades in BIIB

Gilbert Cisneros purchase BIIB on Jan 30, 2026 (amount: $15.00K).
Rob Bresnahan purchase BIIB on May 15, 2025 (amount: $15.00K).
Rob Bresnahan purchase BIIB on Feb 25, 2025 (amount: $15.00K).
Ro Khanna purchase BIIB on Nov 15, 2024 (amount: $15.00K).
Ro Khanna sale BIIB on Sep 9, 2024 (amount: $15.00K).

Latest BIIB News

Biogen Acquires Apellis for $5.3B and Advances Tau Drug, Shares Jump 10% — May 15, 2026
Biogen drops after Phase 2 CELIA diranersen data, despite plan for Phase 3 — May 14, 2026
Biogen Completes $41-Per-Share Apellis Acquisition While Alzheimer’s Drug Misses Primary Endpoint — May 14, 2026
Biogen’s Apellis Acquisition Spurs SmallCap 600 Removal on May 14 — May 7, 2026
Bright Horizons, Remitly Join S&P SmallCap 600 as Apellis and Tri Pointe Exit — May 7, 2026

Recent BIIB Insider Trades

Murphy Nicole bought 3 (~$585.105) on Feb 12, 2026.
Singhal Priya sold 2.66K (~$531.55K) on Feb 9, 2026.
Singhal Priya sold 748 (~$134.12K) on Feb 2, 2026.

BIIB Analyst Consensus

26 analysts cover BIIB: 0 strong buy, 15 buy, 10 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $218.76.

Common questions about BIIB

Which politicians traded BIIB stock?: Recent politician trading activity in BIIB includes disclosures from Gilbert Cisneros, Rob Bresnahan, Rob Bresnahan, Ro Khanna, and Ro Khanna. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in BIIB?: Yes. Rallies tracks politician and congressional stock disclosures for BIIB, including reported purchases, sales, dates, owners, and trade amounts when available.
Is BIIB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for BIIB. It does not provide personalized investment advice.